ADCs are emerging as a promising class of therapeutics across a broad range of lung cancers, with the potential to overcome heterogenous resistance mechanisms of EGFR-mutant NSCLC after TKI progression. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.